GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Intrinsic Value: Projected FCF

TG Therapeutics (TG Therapeutics) Intrinsic Value: Projected FCF : $-8.95 (As of Apr. 29, 2024)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-29), TG Therapeutics's Intrinsic Value: Projected FCF is $-8.95. The stock price of TG Therapeutics is $13.47. Therefore, TG Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for TG Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

TGTX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.32
* Ranked among companies with meaningful Price-to-Projected-FCF only.

TG Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for TG Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Intrinsic Value: Projected FCF Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.67 -5.15 -9.39 -11.43 -8.95

TG Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.43 -11.81 -11.85 -9.04 -8.95

Competitive Comparison of TG Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, TG Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Price-to-Projected-FCF falls into.



TG Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get TG Therapeutics's Free Cash Flow(6 year avg) = $-160.37.

TG Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-160.36848+160.502*0.8)/156.175
=-8.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TG Therapeutics  (NAS:TGTX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

TG Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=13.47/-8.9538192060858
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TG Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (TG Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019

TG Therapeutics (TG Therapeutics) Headlines

From GuruFocus